The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says executives have warned that policies pursued by the government will make the UK a less attractive place to invest.

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in northwest England.

The pharmaceutical giant says the new Labour government has offered less investment than their Conservative predecessors.

AstraZeneca’s manufacturing will-they-won’t-they within its home country has swung back firmly toward the ‘they won’t’ camp after the British pharma confirmed that it’s ditching a major venture at | AstraZeneca is pulling the plug on a 450 million pound sterling investment at its vaccine production site in England due in large part to the reduction of a planned financial contribution from the U.

Scrapping the £450 million vaccine plant deals a major blow to the Labour government’s economic revival plans.

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.